Renal Artery Denervation In Addition to Catheter Ablation To Eliminate Atrial Fibrillation

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 302 participants.

Also called NCT01873352

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 302 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01873352
Other papers using this trial's data
  • Effect of Renal Denervation and Catheter Ablation vs Catheter Ablation Alone on Atrial Fibrillation Recurrence Among Patients With Paroxysmal Atrial Fibrillation and Hypertension: The ERADICATE-AF Randomized Clinical Trial JAMA, 2020-01-21 DOI, PubMed 31961420, PMC6990678 PubMed links an erratum for this paper. Erratum: PMID 32125382 Not in the PMC Open Access subset.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Russia (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01873352. Randomized; single masking; primary purpose treatment. Start 2013-06-20 (actual); primary completion 2019-03-01 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Renal Artery Denervation In Addition to Catheter Ablation To Eliminate Atrial Fibrillation
Acronym
ERADICATE--AF
Condition
Hypertension
Intervention (Procedure)
catheter ablation
Intervention (Procedure)
renal sympathetic denervation
Lead sponsor
Meshalkin Research Institute of Pathology of Circulation (class: research network)

Record details

Record id
cardio:ct-nct01873352
Content hash
f9daec46891a46279500d2e4c62ed33b577968723a6cf8d5a884c2eac9c17f91